Table 2 Clinicopathologic variables
From: Survival in pregnancy-associated breast cancer patients compared to non-pregnant controls
Variable | Non-pregnant (N = 55) | Pregnant (N = 34) | P-value | Missing values | |||||
|---|---|---|---|---|---|---|---|---|---|
Non-pregnant | Pregnant | ||||||||
No | % | No | % | No | % | No | % | ||
Pathology | 0.369 | 3 | 5.5 | 4 | 11.8 | ||||
Unifocal | 41 | 78.8 | 21 | 70 | |||||
Multifocal | 11 | 21.2 | 9 | 30 | |||||
Malignancy Grade | 0.023 | 1 | 1.8 | 3 | 8.8 | ||||
1 | 8 | 14.8 | 0 | ||||||
2 | 26 | 48.1 | 12 | 38.7 | |||||
3 | 20 | 37 | 19 | 61.3 | |||||
Molecular | 0.148 | 3 | 5.5 | 2 | 5.9 | ||||
ER/PR + , Ki67 < 20 | 13 | 25 | 2 | 6.3 | |||||
ER/PR + , Ki67 ≥ 20 | 14 | 26.9 | 9 | 28.1 | |||||
ER/PR + , Ki67 ≥ 20,Her2 + | 10 | 19.2 | 10 | 50 | |||||
Her2 + (ER/PR-) | 6 | 11.5 | 2 | 6.3 | |||||
Triple Negative (ER/PR/HER2 negative) | 9 | 17.3 | 9 | 28.1 | |||||
Pathologic stage (Grouped) | 0.008 | 4 | 7.3 | 0 | |||||
0,I,II | 42 | 82.4 | 19 | 55.9 | |||||
III,IV | 9 | 17.6 | 15 | 44.1 | |||||